- OmniaBio opens the largest Canadian CDMO facility dedicated to cell and gene therapy (CGT) in Hamilton, Ontario.
- The facility will utilise advanced AI and manufacturing technologies to reduce costs and improve quality in CGT production.
OmniaBio Inc., a contract development and manufacturing organisation (CDMO) specialising in cell and gene therapy (CGT), has announced the opening of its new manufacturing and AI centre of excellence in Hamilton, Ontario. The facility is now the largest of its kind in Canada, aimed at advancing the production of transformative therapies and improving access across North America.
Located at McMaster Innovation Park, the 120,000 sq. ft. site is designed to support complex manufacturing needs such as critical cold chain logistics and integrated AI technologies. OmniaBio will collaborate with pharmaceutical companies and academic centres to deliver end-to-end services, from process development to commercial-scale manufacturing.
The first commercial client, MEDIPOST, will use the site to manufacture its stem cell therapy, CARTISTEM®, for treating knee cartilage defects in osteoarthritis patients. According to Mitchel Sivilotti, President and CEO of OmniaBio, “This new facility puts us in a unique position as a specialist commercial CGT manufacturing leader tackling the toughest disease challenges.”
The centre will incorporate advanced technologies, including robotics, biosensors, and machine learning, to reduce production costs, improve product quality, and streamline manufacturing processes. The facility will focus on cellular immunotherapies and iPSC-based therapies initially, marking a significant step in CGT contract manufacturing in the region.
Overview of outsourcing trends 
